Disc Medicine’s Post

2024 was a year of meaningful accomplishments for our #Hematology portfolio, from discussions with the FDA on the registrational pathway for #Bitopertin in #EPP and #XLP to the generation of positive data for DISC-0974 and DISC-3405. As we build on this momentum, we’re excited to advance our clinical programs in 2025, striving toward meaningful progress for patients with #Hematological diseases. Learn more: https://lnkd.in/ePbZARMM #Myelofibrosis #KidneyDisease #PolycythemiaVera

To view or add a comment, sign in

Explore topics